Inotiv

What Inotiv does

Inotiv, Inc. (NASDAQ: NOTV, headquartered in West Lafayette, Indiana) is a nonclinical contract research organization (CRO) providing discovery, translational, and safety assessment services to pharmaceutical, biotechnology, government, and academic customers across North America and Europe. Originally founded as Bioanalytical Systems, Inc. (BASi) in 1974 and rebranded to Inotiv in 2019, the company operates three integrated service lines: Discovery and Translational Sciences (disease pharmacology, DMPK, bioanalysis, computational toxicology, toxicogenomics, targeted proteomics, histology and pathology); Safety Assessment (general and genetic toxicology, safety pharmacology, DART, carcinogenicity, GLP bioanalysis, medical device testing, cell and gene therapy); and Research Models and Services (general purpose and genetically engineered models, contract breeding, surgical services, genetic testing, biospecimen, plus Teklad laboratory animal diets, bedding and enrichment). Supporting platforms include Eusoft Labs LIMS, LabTracks sample tracking, Culex and Raturn automated blood sampling devices, and a digital pathology service with AI-driven whole slide image analysis; in December 2025 the company added a strategic partnership with VUGENE for AI/ML-based multi-omics bioinformatics.

Revenue is generated primarily through professional services contracts with biopharma sponsors and unit-priced research model and Teklad product sales, with two reporting segments: Discovery & Safety Assessment (DSA) services and Research Models & Services (RMS) products. Inotiv sells through direct enterprise field sales teams globally, supplemented by online ordering and dedicated regional customer service. The company employed 3,300+ people across 50+ locations as of recent filings, generated $513 million in FY2025 revenue (up 4.5% year-over-year), and reported $145.4 million in DSA backlog at December 31, 2025 with a 1.16x book-to-bill ratio.

Following an aggressive 2021-2022 acquisition program that included the transformative ~$271 million Envigo deal plus multiple bolt-ons (Plato BioPharma, Gateway Pharmacology, Histion, Protypia, Orient BioResource, Integrated Laboratory Systems, Robinson Services rabbit business, HistoTox Labs, Bolder BioPATH), Inotiv accumulated approximately $488.7 million of funded debt. On June 3, 2026 the company filed for Chapter 11 bankruptcy protection in the Southern District of Texas under a prepackaged plan supported by holders of more than 99% of first lien loans, 85% of PIK notes, and 80% of convertible notes, intended to reduce funded debt by approximately $325.4 million to roughly $163.3 million and exit as a private entity. Operations continue during reorganization, with a disclosed cybersecurity incident in August 2025 and ongoing site consolidation (exit of two leased facilities in Q1 FY2026) bracketing the restructuring period.

Name

Inotiv

Legal name

Inotiv, Inc.

Website

https://inotiv.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Inotiv is a U.S.-based nonclinical contract research organization providing drug discovery, safety assessment, bioanalytical, and research models services to pharmaceutical, biotechnology, government, and academic clients across 50+ global locations with 3,300+ employees.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Testing Laboratories and Services (54138)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

DMPK / ADME & Bioanalysis (HLAGAFAC), In Vivo Pharmacology (Efficacy/PD Models) (HLAGAFAA), Pathology & Histopathology Services (HLAGAFAI), Nonclinical Study Management & Regulatory Writing (IND-enabling) (HLAGAFAN), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Contract research services
• Preclinical drug development
• Research animal models
• Safety assessment services
• Laboratory animal diets

Headquarters

HQ city

West Lafayette

HQ country

United States

HQ region

North America

Offices12 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Discovery & Safety Assessment (DSA) Services: Nonclinical and analytical drug discovery and development services including toxicology, pharmacology, DMPK, bioanalysis, histology, pathology, and safety assessment. Revenue generated from service contracts with pharmaceutical and biotech companies. DSA segment generated $48.0 million in Q1 FY 2026.
2. Research Models & Services (RMS) Products: Sale of research models including small animals, large animals, non-human primates, and genetically engineered models, along with related services. Product revenue from research model sales was $61.158 million in Q1 FY 2026. Includes Teklad laboratory animal diets, bedding, and enrichment products.
3. Contract Breeding and Surgical Services: Contract breeding services, surgical services, genetic testing, and custom breeding for research models.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Inotiv is a contract research organization providing nonclinical drug discovery and development services, safety assessment, and bioanalytical services to pharmaceutical and biotechnology clients. The company also manufactures and sells research animal models, Teklad laboratory animal diets and bedding, and proprietary laboratory tracking software (Eusoft Labs LIMS, LabTracks) to support preclinical research across therapeutic areas from discovery through preclinical phases.

Product overview

Inotiv is a discovery and development contract research organization (CRO) operating as a single unified platform with multiple integrated service divisions. The company offers three core service lines: Discovery and Translational Sciences (providing disease pharmacology, DMPK, bioanalysis, computational toxicology, toxicogenomics, proteomics, histology and pathology), Safety Assessment (including toxicology, pathology, GLP bioanalysis, and cell/gene therapy services), and Research Models and Services (the broadest range of research models including GEMS, surgical services, and breeding). Supporting these core divisions are Teklad laboratory animal diets and bedding, Eusoft Labs LIMS and LabTracks sample tracking systems, digital pathology with AI-driven image analysis, monoclonal antibody production, and ADC bioanalysis assays. The company also maintains Envigo (acquired brand) and BASi Research Products (subsidiary) as sub-brands. The portfolio is unified under a single operational structure where clients can access discovery through approval services, with cross-divisional capabilities in bioinformatics and AI-driven analysis through the VUGENE partnership.

Differentiator

Problem solved

Functional benefit

Brands

• Teklad: Laboratory animal diets, bedding, and environmental enrichment products
• BASi Research Products
• Eusoft Labs
• LabTracks

Products and services

• Discovery and Translational Sciences Comprehensive nonclinical drug discovery services including disease pharmacology (in vitro and in vivo), drug metabolism and pharmacokinetics (DMPK), discovery bioanalysis and biomarkers, cell and molecular biology, predictive and computational toxicology, toxicogenomics, targeted proteomics, histology and pathology, and consultative drug discovery programs for pharmaceutical and biotechnology clients.
• Safety Assessment Nonclinical safety testing services including general and exploratory toxicology, genetic toxicology, safety pharmacology, developmental and reproductive toxicology (DART), carcinogenicity, pathology, GLP bioanalysis for large and small molecules, impurities assessment, medical device testing and surgical support, cell and gene therapy services, program management, and SEND services.
• Research Models and Services Broadest range of research models including general purpose and genetically engineered models (GEMS) for therapeutic areas such as oncology, cardiovascular, and metabolic disease, plus services including contract breeding, surgical services, genetic testing, biospecimen services, and full spectrum health monitoring.
• Teklad Laboratory Animal Diets and Bedding Teklad-branded laboratory animal diets including standard natural ingredient diets, custom research diets, and medicated diets, along with contact bedding, custom-cut paper cage liners, and WelfarePlus+ enrichment products for laboratory animal care.
• Digital Pathology Service Whole slide imaging and precision AI-driven quantitative image analysis services supporting drug discovery and development projects for pharmaceutical and biotechnology clients.
• Monoclonal Antibody Production Custom monoclonal antibody production services for small scale and large scale manufacturing to support therapeutic development for biotech and pharmaceutical clients.
• ADC Bioanalysis Assays

Quantifiable outcome

• DSA segment 12% revenue growth in Q1 FY 2026
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature7 records

Partnerships

Nine partnerships are on record, tiered strategic, minor and core.

• LifeNet HealthstrategicTechnology or Integration · 13 January 2026Leverage LifeNet Health's proprietary platform to advance New Approach Methodologies (NAMs) in translational drug discovery.
• VUGENEstrategicTechnology or Integration · 11 December 2025Strategic collaboration to integrate AI and machine learning capabilities into Inotiv's Discovery & Translational Sciences Division. Inotiv will utilize VUGENE's cloud-based bioinformatics platform to enhance analysis of complex biological data including epigenomic and proteomic datasets, with the goal of improving prediction of drug efficacy and safety in early-stage research.
• VUGENEstrategicTechnology or Integration · 11 December 2025AI-driven drug discovery partnership using multiomics data. VUGENE provides computational technologies while gaining expanded application within real-world research environments.
• Synexa Life SciencesstrategicStrategic or Co-development Partner · 21 October 2021Partnership to establish leading global provider of full-spectrum, preclinical and clinical biotherapeutics and biomarker analysis solutions. Includes Letter of Intent for Center of Excellence for Biotherapeutics and Biomarkers.
• PhoenixBio Co., Ltd.strategicStrategic or Co-development Partner · 10 November 2020Partnership to expand discovery pharmacology offering. Enables access to specialized pharmacology expertise and capabilities.
• BiocytogenminorChannel Partner/ Reseller/ Distributor · 1 March 2020Distribution collaboration for B-NDG triple immunodeficient and humanizable mouse model. Biocytogen distributes Inotiv's specialized mouse models.
• Phlebotics, Inc.coreTechnology or Integration · 4 April 2018Technology alliance for automated blood sampling. Focus on clinical applications of automated blood sampling technology. BASi Culex® Automated Blood Sampling System enables stress-free sampling from freely moving rodents with reduced pain, stress, blood loss, and labor.
• Atlantic PollinationminorImplementation/ SI/ Consulting PartnerConsultancy agreement to provide specialist ecotoxicology consultancy services for Envigo customers. Atlantic Pollination provides bee organization expertise combined with ecotoxicological innovations.
• The Red Beehive CompanyminorImplementation/ SI/ Consulting PartnerConsultancy agreement to provide specialist ecotoxicology consultancy services. The Red Beehive Company provides team of specialists working to improve bee benefits to environment and food chain.

Scale indicators11 records

Recent moves13 records

Expansion highlights5 records

Direct peers

• Pharmaron: China-headquartered preclinical CRO with comparable DMPK, safety assessment, bioanalytical, and research models services. Direct competitor for global pharma preclinical outsourcing.
• WuXi AppTec: Global preclinical and discovery CRO with comparable DMPK, safety assessment, and bioanalytical services. Directly comparable on service breadth and global delivery model, though larger and geographically diversified.
• Charles River Laboratories: Large global CRO with directly overlapping preclinical/Research Models, Safety Assessment, and Discovery services. Closest large-scale analog to Inotiv's integrated discovery-through-preclinical platform.
• Taconic Biosciences: Pure-play research models provider with genetically engineered models and contract breeding services. Directly comparable to Inotiv's Research Models & Services segment.
• Bio-Techne: Life sciences tools and reagents provider including research models, antibodies, and proteomics. Comparable to Inotiv's research models franchise and proteomics/digital pathology adjacencies.
• The Jackson Laboratory: Non-profit research models provider with deep genetically engineered mouse portfolio and associated services. Directly comparable to Inotiv's genetically engineered models and discovery support offerings.
• Evotec SE: Discovery and preclinical CRO with strong capabilities in DMPK, in vivo pharmacology, and integrated drug discovery. Closely comparable to Inotiv's Discovery & Translational Sciences offering.

Broad incumbents

• IQVIA: World's largest CRO with deep preclinical and clinical capabilities. Overlaps with Inotiv in central labs, bioanalysis, and early-phase services, though preclinical is a smaller share of IQVIA's mix.
• Labcorp (Covance): Broad diagnostics and drug development services company with preclinical CRO capabilities inherited from Covance. Competes with Inotiv in central labs, bioanalysis, and early development, though as part of a much wider portfolio.
• Eurofins Scientific: Global testing services giant with significant bioanalytical, ecotoxicology, and pharma services exposure. Comparable to Inotiv's ecotoxicology and bioanalytical offerings as part of a broader testing portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/inotiv
• Xx.com/inotivco

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries13 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inotiv